Side-by-side · Research reference
DSIPvsTirzepatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft8/36 cited
BFDA-ApprovedVerified14/45 cited
DSIP
Sleep modulator · Anti-stress
SQ · Pre-sleep · Daily during cycle
Tirzepatide
GIP+GLP-1 Dual Agonist · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
DSIP
Tirzepatide
Primary target
Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986
GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018
Pathway
Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986
Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022Frias 2018
Downstream effect
Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986
Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022
Feedback intact?
—
Glucose-dependent insulin release preserves physiological feedback
Origin
Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986
39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018
Antibody development
—
—
02Dosage Protocols
Parameter
DSIP
Tirzepatide
Frequency
Once daily, pre-sleep
—
Lower / starter dose
50 mcg pre-sleep
—
Evidence basis
Human-mechanistic + early clinicalSchneider 1986
FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022ZEPBOUND (tirzepatide) injecti 2023
Duration
8–12 weeks per cycle
Indefinite for chronic indication
Reconstitution
Bacteriostatic water
Pre-filled commercial pen. Research vial: bacteriostatic water per label.
Timing
30–60 min pre-sleep
Once weekly, any time of day
Standard dose (weight)
—
5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023Jastreboff 2022
Titration schedule
—
2.5 mg → +2.5 mg every 4 weeks → 15 mg max
Slower titration mitigates GI side effects.
04Side Effects & Safety
Parameter
DSIP
Tirzepatide
Injection site reaction
Mild irritation
Mild erythema, pruritus
Drowsiness
Expected effect (intentional)
—
Vivid dreams
Anecdotally reported
—
Long-term safety
Limited modern RCT data
—
Pregnancy / OB
Avoid
Contraindicated
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023
Hypoglycemia
—
Low as monotherapy; risk with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Diabetic retinopathy
—
Rapid glycemic improvement may transiently worsen
Absolute Contraindications
DSIP
- ·Pregnancy / breastfeeding
- ·Concurrent CNS-depressant therapy without supervision
Tirzepatide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to tirzepatide
Relative Contraindications
DSIP
- ·Severe sleep apnoea (untreated)
- ·Concurrent benzodiazepine / opioid use
Tirzepatide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy
05Administration Protocol
Parameter
DSIP
Tirzepatide
1. Reconstitution
Add 1–2 mL bacteriostatic water to vial.
Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.
2. Injection site
SQ — abdomen. Rotate sites.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
30–60 min pre-sleep.
Once weekly, same day. Day change allowed if ≥3 days separate doses.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.
5. Needle
29–31G insulin syringe.
Pen-supplied. Research vial: 27–31G insulin syringe.